TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16371678

Group type: EXPERIMENTAL
Intervention: Methylphenidate (usual medication)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12226149

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 326
Study: 10447989

Group type: EXPERIMENTAL
Intervention: Right hemisphere-damaged (RHD) speakers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonneurological control subjects
Number of subjects: 0
Study: 8524681

Group type: EXPERIMENTAL
Intervention: Electronic monitoring (capnograph and pulse oximeter)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional monitoring (visual assessment and auscultation)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Capnography (part of electronic monitoring)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pulse oximetry (part of electronic monitoring)
Number of subjects: 39
Study: 2193318

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (31.5 Gy in 3.5 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 138
Study: 389259

Group type: EXPERIMENTAL
Intervention: Mobilisation on the fifth day after myocardial infarction
Number of subjects: 742

Group type: COMPARATOR
Intervention: Mobilisation on the tenth day after myocardial infarction
Number of subjects: 742
Study: 31919768

Group type: EXPERIMENTAL
Intervention: Postgraduate freshmen evaluating nodules using ACR TI-RADS
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Re-evaluation of Group 4 by postgraduate freshmen
Number of subjects: 400
Study: 31769998

Group type: EXPERIMENTAL
Intervention: Drug repurposing candidates identified through integration of pharmacodynamic and marketing variables from DrugBank and genomic data from BioVU.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14 repurposing candidates across 7 disease areas.
Number of subjects: 0
Study: 28676927

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Spinal anaesthesia (SA)
Number of subjects: 119
Study: 25363555

Group type: EXPERIMENTAL
Intervention: First-line therapy (PPI-based triple therapy for seven days)
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Second-line therapy (moxifloxacin-based triple therapy or bismuth-based quadruple therapy)
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Third-line therapy (unused MA or QUAD)
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Patients with resistance to clarithromycin
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Overall treatment adherence
Number of subjects: 2202
Study: 24055124

Group type: EXPERIMENTAL
Intervention: Peak upright bicycle digital echocardiography (UBE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Post-treadmill digital echocardiography (post-TME)
Number of subjects: 86
Study: 21346202

Group type: EXPERIMENTAL
Intervention: Static wrist extensions against gravity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Slow wrist extension and flexion movements
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Movement conditions
Number of subjects: 68
Study: 19738139

Group type: EXPERIMENTAL
Intervention: Empirical antiarrhythmic drug (AAD) therapy for 6 weeks after AF ablation
Number of subjects: 110

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (no-AAD group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Empirical antiarrhythmic drug (AAD) therapy
Number of subjects: 110
Study: 17557041

Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor (PPI) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 0
Study: 15049979

Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: hK2
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: fPSA
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA and hK2 combined
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA, hK2, and fPSA
Number of subjects: 431
Study: 11506059

Group type: EXPERIMENTAL
Intervention: Monounsaturated enriched sunflower oil diet (40% to 42% of energy from fat, 26% to 28% from monounsaturated fat, 40% to 45% from carbohydrate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low fat, high carbohydrate diet (22% to 25% of energy from total fat, 7% to 8% of energy from monounsaturated fat, 55% to 60% of energy from carbohydrate)
Number of subjects: 28
Study: 9772944

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 19435
Study: 7917776

Group type: EXPERIMENTAL
Intervention: Transdermal morphine (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg over 20 min)
Number of subjects: 12
Study: 3045441

Group type: EXPERIMENTAL
Intervention: Lithium (Li) therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29131513

Group type: EXPERIMENTAL
Intervention: Vascular ultrasound scanning (VUS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (operator's discretion)
Number of subjects: 300
Study: 26797697

Group type: EXPERIMENTAL
Intervention: PRP (Platelet-Rich Plasma)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PRP+HA (Platelet-Rich Plasma + Hyaluronic Acid)
Number of subjects: 111

Group type: COMPARATOR
Intervention: HA (Hyaluronic Acid)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PRP+HA
Number of subjects: 111
Study: 25712473

Group type: EXPERIMENTAL
Intervention: Skin‐to‐skin rewarming
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiant rewarming
Number of subjects: 200
Study: 23085153

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily for six months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20807463

Group type: EXPERIMENTAL
Intervention: New energy requirement model for controlling energetic intake
Number of subjects: 434
Study: 18676693

Group type: EXPERIMENTAL
Intervention: Aplaviroc (GW873140)
Number of subjects: 0
Study: 16669728

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 12784273

Group type: EXPERIMENTAL
Intervention: 450 U of botulinum toxin type A (Dysport) injected into the parotids and submandibular glands
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 ml of placebo injected into the parotids and submandibular glands
Number of subjects: 20
Study: 11171715

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study: 9169997

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography (HPLC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-HPLC measurement
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HPLC measurement
Number of subjects: 41
Study: 1554077

Group type: EXPERIMENTAL
Intervention: Augmented anterior cruciate ligament repair with the iliotibial band
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conservative treatment of the anterior cruciate ligament
Number of subjects: 107
Study: 4019257

Group type: EXPERIMENTAL
Intervention: 100 mg ascorbic acid twice a day for 60 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sugar placebos
Number of subjects: 54
Study: 31026185

Group type: EXPERIMENTAL
Intervention: Mental health promotion program (12 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 86
Study: 28389610

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 487
Study: 26205023

Group type: EXPERIMENTAL
Intervention: 2000 IU/day edible vitamin D for 15 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 23697585

Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA (fish oil) 6 × 1 g capsules/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (monounsaturated oil) 6 × 1 g capsules/d
Number of subjects: 35
Study: 21550907

Group type: EXPERIMENTAL
Intervention: PROMUS Element platinum chromium everolimus‐eluting stent (EES)
Number of subjects: 100
Study: 19489494

Group type: EXPERIMENTAL
Intervention: Surrounded needling therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (Indomethacin and Allopurinol)
Number of subjects: 60
Study: 17272406

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (8-10 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment (8-10 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Episodic hypoxia (after treatment with testosterone or placebo)
Number of subjects: 11
Study: 12527970

Group type: EXPERIMENTAL
Intervention: Magnitopuncture applied to Dazhui (DU14) and Neiguan (PC6) points
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-acupuncture points (1.5 cm away from DU14 and PC6)
Number of subjects: 40
Study: 10561314

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) measurements of thoracic ratio (TR)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Longest diameter of the largest individual nodal mass (LIM(CT)) greater than 10 cm
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chest Radiography (CXR) measurements of thoracic ratio (TR)
Number of subjects: 95
Study: 10180870

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 97

Group type: COMPARATOR
Intervention: Indifferent patients
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional GP management
Number of subjects: 97
Study: 1679645

Group type: EXPERIMENTAL
Intervention: 1 mg flumazenil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher doses of flumazenil (2-5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7041850

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Simple exercise therapy
Number of subjects: 22
Study: 6691783

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CT plus pharmacotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: CT plus active placebo
Number of subjects: 87
Study: 31664593

Group type: EXPERIMENTAL
Intervention: Dental services received by children up to 6 years old in eastern regions of Austria
Number of subjects: 130895

Group type: EXPERIMENTAL
Intervention: Children needing more than four dental services
Number of subjects: 130895

Group type: COMPARATOR
Intervention: Smaller random sample of 3000 children
Number of subjects: 130895
Study: 28333879

Group type: EXPERIMENTAL
Intervention: Sustained Group (monthly IAI for 3 months, then every 2 months for 12 months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PRN Group (1 IAI at randomization, then monthly PRN IAI for 12 months)
Number of subjects: 39
Study: 27995141

Group type: EXPERIMENTAL
Intervention: 2D laparoscopic platform
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic platform
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2D and 3D laparoscopic platforms
Number of subjects: 10
Study: 24161334

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) for technically inoperable patients (TI)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) for clinically inoperable patients (CLI)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard therapy for both TI and CLI patients
Number of subjects: 369
Study: 22403196

Group type: EXPERIMENTAL
Intervention: Wellness Portal
Number of subjects: 538

Group type: COMPARATOR
Intervention: Control
Number of subjects: 538
Study: 20487567

Group type: EXPERIMENTAL
Intervention: Neuragen PN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18545057

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/day, intravenous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15918128

Group type: EXPERIMENTAL
Intervention: Anterior capsulolaboral reconstruction according to Jobe
Number of subjects: 24
Study: 12840614

Group type: EXPERIMENTAL
Intervention: Various treatment procedures including epidural steroids, trigger point injections, and cognitive-behaviorally oriented psychoeducational groups
Number of subjects: 74
Study: 11142163

Group type: EXPERIMENTAL
Intervention: 5-FU/Leucovorin (LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous intraportal 5-FU infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU and levamisol (LEV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT/LV (oral chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT alone
Number of subjects: 0
Study: 8864039

Group type: EXPERIMENTAL
Intervention: Females (with a tendency to turn towards the right)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males (with a tendency to turn towards the right)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Females using oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regularly cycling females
Number of subjects: 0
Study: 1522191

Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IUI/superovulation
Number of subjects: 151
Study: 6361628

Group type: EXPERIMENTAL
Intervention: Nabumetone, 500 mg two nocte
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen, 250 mg two nocte and one mane
Number of subjects: 24
Study: 31609677

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal (UGI) series
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Lower gastrointestinal (LGI) series
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram (VCUG)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Modified barium swallow (MBS)
Number of subjects: 162
Study: 29994994

Group type: EXPERIMENTAL
Intervention: Adelta fiber activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: C fiber activation
Number of subjects: 0
Study: 27596132

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 2 g/day
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 24067785

Group type: EXPERIMENTAL
Intervention: hyperimmune caprine serum (AIMSPRO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 22070919

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS preceded by 5 minutes of 6 Hertz rTMS (priming rTMS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-frequency rTMS without priming
Number of subjects: 23
Study: 20512064

Group type: EXPERIMENTAL
Intervention: Chest press exercise at 44 degrees
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chest press exercise at 56 degrees
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chest press exercise at 0 degrees
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chest press exercise at 28 degrees
Number of subjects: 15
Study: 17928580

Group type: EXPERIMENTAL
Intervention: IV ceftriaxone
Number of subjects: 37

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 37
Study: 15950657

Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study: 11830339

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 164
Study: 10513357

Group type: EXPERIMENTAL
Intervention: Posteromedial release
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete circumferential subtalar release
Number of subjects: 20
Study: 7560220

Group type: EXPERIMENTAL
Intervention: Buffered 0.3% acetylsalicylic acid (ASA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water (500 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal oral hygiene alone
Number of subjects: 60
Study: 1834396

Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg b.i.d.)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-dosage aspirin (300 mg/die)
Number of subjects: 87
Study: 7127989

Group type: EXPERIMENTAL
Intervention: Syringe for medication delivery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Teaspoon for medication delivery
Number of subjects: 72
Study: 31577372

Group type: EXPERIMENTAL
Intervention: Plain English abstracts
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Visual abstracts
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard tweets
Number of subjects: 41
Study: 30291068

Group type: EXPERIMENTAL
Intervention: PilAm Go4Health intervention (3 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waitlist control (received PilAm Go4Health in phase 2)
Number of subjects: 45
Study: 25763524

Group type: EXPERIMENTAL
Intervention: Lidcombe Program without instruction to parents to use the verbal contingency request for self-correction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard Lidcombe Program
Number of subjects: 34
Study: 23911864

Group type: EXPERIMENTAL
Intervention: SRP+aPDT
Number of subjects: 15
Study: 20215488

Group type: EXPERIMENTAL
Intervention: Once-weekly gym-based exercise programme
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Twice-weekly gym-based exercise programme
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 106
Study: 19860300

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 115
Study: 16399292

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 280
Study: 15250255

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3 g/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11236069

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg three times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9315414

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol and 2.00 mg dienogest
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8363115

Group type: EXPERIMENTAL
Intervention: 1% diphenhydramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 10
Study: 3527109

Group type: EXPERIMENTAL
Intervention: Transderm scopolamine disc
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29099421

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily with propranolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 23
Study: 27572290

Group type: EXPERIMENTAL
Intervention: Optia
Number of subjects: 154

Group type: COMPARATOR
Intervention: Spectra-Auto
Number of subjects: 154
Study: 26259978

Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pen injection of insulin aspart
Number of subjects: 20
Study: 24050578

Group type: EXPERIMENTAL
Intervention: 400mg caper fruit extract three times a day for two months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo capsules three times a day for two months
Number of subjects: 54
Study: 21878082

Group type: EXPERIMENTAL
Intervention: fixed combination amlodipine/valsartan
Number of subjects: 86

Group type: COMPARATOR
Intervention: traditional therapy
Number of subjects: 86
Study: 19407662

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg b.i.d.)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Pantoprazole (40 mg b.i.d.)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers (EMs)
Number of subjects: 178

Group type: COMPARATOR
Intervention: CYP2C19 poor metabolizers (PMs)
Number of subjects: 178
Study: 17028853

Group type: COMPARATOR
Intervention: MRI finding of post‐traumatic neuroma
Number of subjects: 31

Group type: COMPARATOR
Intervention: MRI finding of pseudomeningocele
Number of subjects: 31
Study: 14871464

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 11728960

Group type: EXPERIMENTAL
Intervention: sFas levels in patients with CAD (n = 64)
Number of subjects: 107

Group type: COMPARATOR
Intervention: sFas levels in patients without CAD (n = 43)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: sFas levels
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Increase of one quintile in plasma concentration of sFas
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Models incorporating sFas
Number of subjects: 107
Study: 9210707

Group type: EXPERIMENTAL
Intervention: Combined immunotherapy with IL-2 and LAK cells after chemotherapy or radiotherapy (Group A)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control standard therapy (Group B)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Combined immunotherapy (Group A)
Number of subjects: 174
Study: 7712675

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (50 micrograms/puff)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (100 micrograms/puff)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flunisolide (250 micrograms/puff)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flunisolide (one puff four times a day, increased after 1 week and 2 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (two puffs four times a day, increased after 1 week and 2 weeks)
Number of subjects: 25